Cigna announced on May 11 that it had signed value-based contracts to cover evolocumab (Repatha) and alirocumab (Praluent).

A new report from GlobalData estimates the market for heart failure treatments is expected to grow from $3.2 billion in 2015 to $11.8 billion in 2025, representing a 13.7 percent compound annual growth rate.

An overview of 35 systematic reviews of randomized clinical trials found that aspirin, blood pressure-lowering therapies and statins reduced the risk of primary atherosclerotic cardiovascular disease by 10 percent to 25 percent in adults without prevalent atherosclerotic cardiovascular disease.

In 2013, the NBA and Columbia University began a collaboration in which all of the NBA’s echocardiograms were assessed by a cardiologist at Columbia.

DUBLIN and SAN FRANCISCO - May 5, 2016 - Medtronic plc (NYSE:MDT) today announced clinical results highlighting the strong safety and performance profile of the miniaturized Micra® Transcatheter Pacing System (TPS) at Heart Rhythm 2016, the Heart Rhythm Society's 37th Annual Scientific Sessions in San Francisco.

An analysis of nearly 10,000 patients with atrial fibrillation who underwent ablation found that healthcare expenditures decreased 40 percent in a year among patients who experienced no clinical events following the ablation. Meanwhile, patients who received a prescription for an antiarrhythmic drug, had another ablation or had pulmonary edema had an increase in costs.

Patients with type 2 diabetes who took saxagliptin or sitagliptin had a similar risk for hospitalized heart failure compared with those who received antihyperglycemic agents, according to a retrospective cohort study.

Since 2006, the National Basketball Association (NBA) has required all players to undergo stress echocardiograms during each preseason. It is the only U.S. professional sports league with such a cardiac program.